{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Brivaracetam+tablets", "query": { "intervention": "Brivaracetam tablets" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 19, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Brivaracetam+tablets&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-05T15:43:56.557Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00368251", "title": "Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Unverricht-Lundborg Disease" ], "interventions": [ { "name": "Placebo", "type": "OTHER" }, { "name": "BRV 2.5 mg", "type": "DRUG" }, { "name": "BRV 25 mg", "type": "DRUG" }, { "name": "BRV 50 mg", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "UCB Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 56, "start_date": "2006-11", "completion_date": "2008-01", "has_results": true, "last_update_posted_date": "2023-05-31", "last_synced_at": "2026-09-05T15:43:56.557Z", "location_count": 4, "location_summary": "San Francisco, California • Gainesville, Florida • New York, New York + 1 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "New York", "state": "New York" }, { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00368251" }, { "nct_id": "NCT01364597", "title": "Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Epilepsy" ], "interventions": [ { "name": "Brivaracetam (BRV)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UCB Pharma SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "28 Days", "maximum_age": "17 Years", "sex": "ALL", "summary": "28 Days to 17 Years" }, "enrollment_count": 257, "start_date": "2011-08-01", "completion_date": "2022-02-03", "has_results": true, "last_update_posted_date": "2025-10-20", "last_synced_at": "2026-09-05T15:43:56.557Z", "location_count": 15, "location_summary": "Los Angeles, California • Gulf Breeze, Florida • Wellington, Florida + 12 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Gulf Breeze", "state": "Florida" }, { "city": "Wellington", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01364597" }, { "nct_id": "NCT01405508", "title": "Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Epilepsy" ], "interventions": [ { "name": "Brivaracetam tablets", "type": "DRUG" }, { "name": "Brivaracetam bolus", "type": "DRUG" }, { "name": "Brivaracetam infusion", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "UCB Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "16 Years to 70 Years" }, "enrollment_count": 105, "start_date": "2011-08", "completion_date": "2012-07", "has_results": true, "last_update_posted_date": "2018-07-11", "last_synced_at": "2026-09-05T15:43:56.557Z", "location_count": 8, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Lexington, Kentucky + 5 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01405508" }, { "nct_id": "NCT05109234", "title": "A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Childhood Absence Epilepsy", "Juvenile Absence Epilepsy" ], "interventions": [ { "name": "Brivaracetam Film-coated tablet", "type": "DRUG" }, { "name": "Brivaracetam oral solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UCB Biopharma SRL", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "26 Years", "sex": "ALL", "summary": "2 Years to 26 Years" }, "enrollment_count": 84, "start_date": "2022-03-30", "completion_date": "2025-03-18", "has_results": true, "last_update_posted_date": "2025-10-22", "last_synced_at": "2026-09-05T15:43:56.557Z", "location_count": 5, "location_summary": "Birmingham, Alabama • Orange, California • Augusta, Georgia + 2 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Orange", "state": "California" }, { "city": "Augusta", "state": "Georgia" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05109234" }, { "nct_id": "NCT01261325", "title": "Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Epilepsy" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Brivaracetam", "type": "DRUG" }, { "name": "Antiepileptic drugs with market authorization available per country", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UCB Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "16 Years to 80 Years" }, "enrollment_count": 768, "start_date": "2010-12", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2022-07-22", "last_synced_at": "2026-09-05T15:43:56.557Z", "location_count": 61, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 52 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01261325" }, { "nct_id": "NCT02088957", "title": "Efficacy Evaluation of Intravenous Brivaracetam and Phenytoin in Subjects With Nonconvulsive Electrographic Seizures", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Nonconvulsive Electrographic Seizures" ], "interventions": [ { "name": "Brivaracetam intravenous solution", "type": "DRUG" }, { "name": "Brivaracetam oral tablets", "type": "DRUG" }, { "name": "Phenytoin intravenous solution", "type": "DRUG" }, { "name": "Phenytoin oral tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UCB BIOSCIENCES, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 1, "start_date": "2014-03", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2018-07-11", "last_synced_at": "2026-09-05T15:43:56.557Z", "location_count": 2, "location_summary": "Lexington, Kentucky • Jackson, Mississippi", "locations": [ { "city": "Lexington", "state": "Kentucky" }, { "city": "Jackson", "state": "Mississippi" } ], "official_url": "https://clinicaltrials.gov/study/NCT02088957" }, { "nct_id": "NCT00150800", "title": "This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Epilepsy" ], "interventions": [ { "name": "Brivaracetam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UCB PHARMA Inc. (US)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 668, "start_date": "2006-01", "completion_date": "2017-09", "has_results": true, "last_update_posted_date": "2021-08-17", "last_synced_at": "2026-09-05T15:43:56.557Z", "location_count": 46, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 38 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00150800" }, { "nct_id": "NCT00761774", "title": "An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Epilepsy" ], "interventions": [ { "name": "Brivaracetam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UCB Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 108, "start_date": "2008-11", "completion_date": "2017-03", "has_results": true, "last_update_posted_date": "2018-07-11", "last_synced_at": "2026-09-05T15:43:56.557Z", "location_count": 25, "location_summary": "Phoenix, Arizona • Fresno, California • Pasadena, California + 22 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00761774" }, { "nct_id": "NCT00464269", "title": "Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Epilepsy" ], "interventions": [ { "name": "Placebo", "type": "OTHER" }, { "name": "Brivaracetam 2.5 mg", "type": "DRUG" }, { "name": "Brivaracetam 10 mg", "type": "DRUG" }, { "name": "Brivaracetam 25 mg", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "UCB Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "16 Years to 70 Years" }, "enrollment_count": 400, "start_date": "2007-09", "completion_date": "2009-01", "has_results": true, "last_update_posted_date": "2022-07-21", "last_synced_at": "2026-09-05T15:43:56.557Z", "location_count": 40, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 37 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Fresno", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00464269" }, { "nct_id": "NCT00699283", "title": "A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Epilepsy" ], "interventions": [ { "name": "Brivaracetam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UCB Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "16 Years to 75 Years" }, "enrollment_count": 62, "start_date": "2008-08", "completion_date": "2010-03", "has_results": true, "last_update_posted_date": "2018-07-11", "last_synced_at": "2026-09-05T15:43:56.557Z", "location_count": 43, "location_summary": "Little Rock, Arkansas • Garden Grove, California • Loma Linda, California + 40 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Garden Grove", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Riverside", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00699283" } ] }